Breaking News in the Cannabis & Novel
Medicines Industry
30 September 2021
Independent Expert Panel on MDMA and psilocybin (TGA)
Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions.
​21 September 2021
Nicotine Vaping Products (TGA)
Information on legally access Nicotine vaping products in Australia.
26 April 2021
Global Antidepressants Market Report 2021
COVID-19 Causes a Surge in Demand for Antidepressant Drugs as Mental Health Problems Rise.
2021
Psychedelic Invest
Psychedelics are changing psychiatry and set to disrupt the alcohol, tobacco, pharmaceutical and health and wellness industries. Psychedelic Invest has said there an enormous opportunity for early investors whom are foresighted enough to look past the biased and manipulated stigma imposed on many psychedelics.
27 January 2021
How ecstasy and psilocybin are shaking up psychiatry
Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.
10 February 2020
Psychedelics move from agents of rebellion towards therapeutics
Once agents of the anti-establishment, psychedelics are now moving to the commercial market, with regulatory approvals and phase 3 trials opening the door to mainstream therapeutics.
​13 February 2019
Antidepressant based on party drug gets backing from FDA advisory group
US regulatory agency could soon approve esketamine to treat depression, but questions remain about the compound's efficacy and potential for abuse.
28 April 2017
Psychedelic compound in ecstasy moves closer to approval to treat PTSD
US regulatory agency could soon approve esketamine to treat depression, but questions remain about the compound's efficacy and potential for abuse.
28 April 2017
First look at LSD in action reveals acid-trip biochemistry
Studies reveal drug's crystal structure and how it affects people's perceptions of meaning.
17 May 2016
Magic-mushroom drug lifts depression in first human trial
A hallucinogenic drug derived from magic mushrooms could be useful in treating depression, the first safety study of this approach has concluded.